Background: Cardiac tamponade is a rare but life-threatening complication of systemic lupus erythematosus (SLE). Aims/Objectives: To describe incidence, risk factors and treatment of cardiac tamponade in a large cohort of Indian patients with SLE. Methods: This retrospective study was conducted at the Department of Rheumatology, IPGMER, Kolkata, India from May 2014 to December 2016 on admitted patients with SLE. Lupus-related serositis was diagnosed after excluding other causes, such as infection, malignancy or heart failure. Results: Of 409 patients with SLE, pericarditis was diagnosed in 25.4% (104/409) and cardiac tamponade in 5.9% (24/409). Tamponade was the presenting feature of SLE in 50% (12/24). Tamponade occurred in 77.8% (14/18) of large effusions and in 11.63% (10/86) of small-to-moderate effusions. The commonest autoantibody in serum and pericardial fluid was anti-nucleosme antibody. Large pericardial effusion (>20 mm) (Odd's ratio (OR): 93.2, 95% confidence interval (CI): 11.1-782.5, P < 0.001) predicted tamponade. In the subset of patients with small-to-moderate sized pericardial effusion, tamponade was associated with pleuritis (OR: 44.5, 95% CI: 1.6-1243, P ¼ 0.025), anti-nucleosome antibody (OR: 42.9, 95% CI: 1.6-1176, P ¼ 0.026) and size of pericardial effusion (OR: 1.36, 95% CI: 1.04-1.76, P ¼ 0.025). Repeated pericardiocentesis was required in 3 patients and one needed surgical intervention. Immunosuppressives used were: prednisolone with monthly intravenous cyclophosphamide (in 33.33%) and intravenous methylprednisolone with monthly cyclophosphamide (in 50%). Conclusions: Pleuritis, anti-nucleosome antibody and size of pericardial effusion predicted development of tamponade. High dose immunosuppression (methylprednisolone and IV cyclophosphamide) alleviated need for surgery in majority.
Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with worldwide prevalence that affects almost all organs of the body. 1 Serosal involvement is common in SLE and has been consistently included in American College of Rheumatology (ACR) classification criteria of lupus over the years 1982 and 1997 and later in the Systemic Lupus Collaborating Clinics (SLICC) 2012 classification criteria. 2 Pericarditis is the commonest cardiac manifestation of lupus occurring in around 9-54% of patients with lupus. Cardiac tamponade, is much rarer with incidence <2.5%. 3 There are only a handful of studies describing in details the disease process, therapeutics and predictors of development of tamponade in patients with lupus. [3] [4] [5] [6] [7] Therefore, the objective of the current study is to estimate incidence of cardiac tamponade in patients with SLE, to describe their clinical features and treatment and to investigate predictors in patients with SLE.
Materials and methods
This retrospective hospital based observational study was conducted at the Department of Rheumatology, Institute of Post Graduate Medical Education and Research (IPGMER), Kolkata, India, a tertiary care referral centre.
Patients diagnosed with SLE in the Department of Rheumatology, IPGMER from May 2014 to December 2016 were included retrospectively through electronic records.
SLE was diagnosed according to the Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria. 2 Following definitions for pericarditis and tamponade are used throughout this paper. Lupus-related serositis was diagnosed after excluding other causes, such as infection, malignancy or heart failure. Pericarditis was diagnosed with the following criteria:
i. Clinical criteria: typical precordial sharp pain; pericardial rub; ii. Characteristic electrocardiographic abnormalities; iii. Either current or subsequent (following clinical symptoms, as above) development of echocardiographic pericardial effusion.
Echocardiographic criterion was mandatory and in combination with any of clinical and electrocardiographic criteria constituted a diagnosis of pericarditis.
Cardiac tamponade was diagnosed from echocardiographic record and diastolic right atrial and ventricular indentation or collapse on 2D echocardiography was taken as diagnostic. 8 Following additional data were also collected: demographic data (age, sex, duration of disease in months, juvenile onset vs. adult onset SLE); organ involvements (as per definition of SLICC 2012 classification criteria and SLEDAI 2 K components, namely, neuropsychiatric lupus (NPSLE) including both psychiatric and organic manifestation and seizure, optic neuritis, arthritis, myositis, lupus nephritis (LN), mucocutaneous involvement and fever), 2,9 other lupus-related manifestations (autoimmune haemolytic anaemia (AIHA), pancreatitis), Systemic Lupus Erythematosus Disease Activity Index-2 K (SLEDAI 2000) and laboratory findings (dimension of pericardial effusion by echocardiography (maximum linear dimension in millimeter is noted with categorization as small (<10 mm), medium (10-20 mm) and large (>20 mm)), 3 haemoglobin (gm/dl), total leucocyte count (/ll) and platelet count (/ll), complement C3 level and C4 in mg/dl (Nephelometry) and the following autoantibodies (EUROIMMUNE) entered as dichotomous variables (positive or negative): anti-dsDNA, anti-RNP, anti-Sm, anti-Ro60, antiRo52, anti-La, anti-nucleosome, anti-Histone and antiRibosomal P). Leucopenia was defined as count below 3000/ll and thrombocytopenia as count below 100 000/ll. For patients with tamponade, pericardial fluid analyses were noted, if available, along with treatment and outcome data.
Exclusion criteria
The records with following deficits were excluded: records with insufficient data to classify a patient as SLE as per SLICC 2012 criteria; no clear cut mention of echocardiographic features (size of effusion, haemodynamics, information of diastolic chamber collapse etc); unclear cause attribution for tamponade. Specifically, records were checked for microbiological tests (pericardial fluid for Gram stain, Ziehl-Neelsen stain for tuberculosis (TB) and fungal stain, aerobic bacterial culture and polymerase chain reaction for TB; blood culture, sputum examination for TB and tuberculin skin test). Records, which showed positivity towards identification of an organism, were excluded. However, records which showed positivity towards tuberculin test only without any other microbiological test positivity towards tuberculosis and those who were not being treated with anti-tubercular drug at the time of admission or within a month of discharge were included. Records that showed HIV positivity were also excluded. Other exclusions were: untreated decompensated heart failure, untreated severe hypothyroidism, end stage renal disease or moderate to severe pulmonary hypertension.
Statistical methods
Continuous data were presented as mean 6 standard deviation (SD) and categorical data as number (proportion Separate univariate analyses were done, comparing clinical and laboratory features between patients with or without tamponade. Variables with P < 0.05 in univariate analysis were entered in a multivariable logistic regression model. In a separate exploratory sub-analysis, the latter model was retested in a subset of patients with small to moderate sized pericardial effusions only. All statistical analyses were done using SPSS ver. 16 (SPSS Inc., Chicago, IL, USA).
Results
From May 2014 to December 2016, after application of exclusion criteria, 409 unique case records of patients with SLE were identified (mean age 27.6 6 9. Among patients with lupus nephritis, 151 records had data on renal biopsy status. The following renal biopsy classes were observed: class III (18.5%, 28/151), class IV (62.9%, 95/151), class V (7.9%, 12/151), combined class III/V (2.6%, 4/151) and combined class IV/V (7.9%, 12/151). Compared to patients without pericarditis, SLE patients with pericarditis had higher frequency of pleuritis (7.5% (23/305) vs. 22.1% (23/104), respectively, P < 0.001), myocarditis (2.3% (7/305) vs. 14.4% (15/104), respectively, P < 0.001), anti-RNP positivity (40% (122/305) vs. 52.88% (55/104), respectively, P ¼ 0.022) and lower frequency of anti-histone antibody (13.77 (42/305) vs. 4.81% (5/104), respectively, P ¼ 0.01).
Demographics, clinical and laboratory features
Among the 104 patients with pericardial effusion 24 (23.1%, 95% confidence interval (95% CI): 16.03-32.05) had cardiac tamponade. Tamponade was the presenting feature in half of the cases (50%, 12/24). Following clinical features were noted in patients with tamponade: shortness of breath (100%, 24/24), chest pain (45.8%, 11/24), hypotension (33.3%, 8/24) and raised jugular venous pressure (50%, 12/24). Most of the patients with tamponade had large effusions (58.3%, 14/24) with 29.2% having moderate effusion (7/24) and only 3 had small effusions (12.5%). On the other hand tamponade occurred in 77.8% (14/18) of large effusions and in 11.63% (10/86) of small-to-moderate effusions.
In patients with pericarditis, other organ system involvements in decreasing order of frequency were: fever (79.2%), pleuritis (58.3%), nephritis (54.2%), myositis (45.8%), mucocutaneous (45.8%), polyarthralgia (37.5%), AIHA (20.8%), pancreatitis (16.7%), myocarditis (8.3%), optic neuritis (8.3%) and psychosis (4.2%).
Twenty-two out of these 24 pericardiocentesis samples with complete reports were available. Median pericardial fluid cell count were 400 (interquartile range 74.5-875), mean lymphocyte percentage 73.4 6 34, median protein concentration 4.2 gm/dl (IQR 3.5-5.6), mean pericardial fluid glucose level 82.7 6 30.1 mg/dl, and median adenosine deaminase (ADA) level was 10 IU/L (IQR: 6.75-13.25). Pericardial fluid complement levels were: C3, median 23 mg/dl (IQR: 18-27.25) and C4, median 6.5 mg/dl (IQR 6-8). Autoantibodies in pericardial fluid were available in five patients as follows: anti-nucleosome (80%); anti-RNP, anti-Sm and antiribosomal P (60% each), anti-Ro60 and anti-dsDNA (40% each) and anti-Ro52 (20%).
Comparison of clinical and laboratory parameters between patients with and without tamponade are given in Tables 1 and  2 , respectively. Patients with tamponade were older with later onset of SLE symptoms. These patients also had higher prevalence of pleuritis, pancreatitis and anti-nucleosome antibody positivity. Patients with tamponade had similar SLEDAI compared to those without tamponade (26.4 6 8.4 vs., 26.3 6 7, P ¼ 0.96, respectively).
Treatment and outcome of tamponade
All patients with tamponade underwent pericardiocentesis and three of them underwent multiple pericardiocentesis (two in one and four in two). One patient required surgical intervention. Immunosuppresives used were: oral 1-mg/kg/day prednisolone only (16.6%, 4/24); 1-mg/kg/day prednisolone with monthly intravenous cyclophosphamide (750-1000-mg/dose) (33.33%, 8/24); intravenous methylprednisolone (1000-mg/day for 3 days in two patients; 1000-mg/day for 3 days followed by 125-mg/day for 5 days in one; 500-mg/day for 3 days in seven patients and 500-mg/day for 2 days in two patients) followed by 1-mg/kg/day prednisolone with monthly intravenous cyclophosphamide (750-1000-mg/dose) (50%, 12/24). One patient in the last group was given only two doses of cyclophosphamide and further treated with Rituximab due to worsening clinical condition. Two patients died (case fatality rate 8.3%, 95% CI: 2.3-25.8).
Among the 22 surviving patients initial and 6-month oral daily prednisolone doses (mg/day) were 37.9 6 7.9 and 9.7 6 3.5, respectively. Eighteen patients were on monthly cyclophosphamide infusions (six such in each) and cumulative dose of cyclophosphamide was 4055 6 745 mg. All of the 22 patients had at least 6 months of follow up. Three patients were lost to follow up within the first year (two after 8 months and one after the 9th month). Overall median duration of follow-up was 18 months (interquartile range 12-24 months).
Predictors of cardiac tamponade
Binary logistic regression model was done with the presence of tamponade as dependent variable and the following independent variables: age, age of onset of SLE, pleuritis, pancreatitis, anti-nucleosome antibody and dimension of pericardial effusion (small, moderate or large). Association with large pericardial effusion size (OR: 93.2, 95% CI: 11.1-782.5, P < 0.001) and a trend with anti-nucleosome antibody (OR: 6.36, 95% CI: 0.94-429, P ¼ 0.058) were observed (Hosmer Lemeshow test Chi-square 6.2, df ¼ 8, P ¼ 0.6, Nagelkarke R squared ¼ 0.71). In the sub-group of patients with small-to-moderate pericardial effusions (n ¼ 10), in univariate analysis the following significant associations were noted: dimension of pericardial effusion (11.6 6 3.4 mm vs. 7.3 6 4.1 mm, P ¼ 0.002), pleuritis (70% (7/10) vs. 13.3% (8/75), P < 0.001), pancreatitis (40% (4/10) vs. 0, P < 0.001) and anti-nucleosome antibody (60% (6/10) vs. 18.4% (14/76), P ¼ 0.004). In this sub-group of patients with small-tomoderate sized pericardial effusion, another binary logistic regression model was fitted with the presence of tamponade as dependent variable and the following independent variables: age, age of onset of SLE, pleuritis, pancreatitis, anti-nucleosome antibody positivity and dimension of pericardial effusion in millimetres (Nagelkarke R squared 0.71). Following were significant associations: pleuritis (OR: 44.5, 95% CI: 1.6-1243, P ¼ 0.025), anti-nucleosome antibody (OR: 42.9, 95% CI: 1.6-1176, P ¼ 0.026) and dimension of pericardial effusion (OR: 1.36, 95% CI: 1.04-1.76, P ¼ 0.025). Each millimetre increase in pericardial effusion size was associated with 36% increased odds of tamponade.
Discussion
Pericarditis occurred in one fourth of our cohort of SLE patients and one fourth of these patients developed cardiac tamponade. Half of these tamponade episodes were presenting feature of lupus. Two previous studies reported that 27-40% of patients have tamponade as a presenting feature. 4, 6 Tertiary care centre with intra-disciplinary co-operation (referral from Cardiology), referral bias and increased awareness are possible reasons for early presentation in the present study.
With the help of electronic record keeping, we could detail the treatment modalities employed for management of tamponade. As with most studies, pericardiocentesis is important. Pericardial window was required in 55% (5/9) of patients in a previous study, 3 due to repeated reaccumulation, but only three of our patients (12.5%, 3/24) required repeated aspiration and only one needed surgical intervention. This is possibly related to earlier use of immunosuppressive regimens alleviating the need for surgical procedures in the majority. Regarding regimens, IV methylprednisolone (500-1000-mg/day for 2-3 days) followed by either 1-mg/kg/day prednisolone directly or short term 125-mg/day methylprednisolone followed by 1-mg/kg/day prednisolone in conjunction with IV cyclophosphamide monthly pulses (750-1000-mg/dose) appear to be highly effective. There is no high quality data on immunosuppressive regimen in lupus-related tamponade except one small study where one patient received cyclophosphamide and most other reports generally report prednisolone only and a few studies have used colchicine but not in tamponade. 3, 10, 11 In our experience, more than half of our patients with tamponade had concomitant lupus nephritis and many others had other severe organ manifestation like myositis, pancreatitis and AIHA necessitating prednisolone and other immunosuppressive agents (cyclophosphamide in most cases). Only two of our patients with tamponade did not have any other major organ involvement related to lupus. Therefore, it appears that immunosuppression, preferably with IV methylprednisolone and pulse cyclophosphamide with adjutant pericardiocentesis, is required and effective in lupus related tamponade. Only a handful of studies reported on predictive factors and incidence of tamponade in lupus patients. These include size of pericardial effusion (Merce et al., 71 patients, 12 the best of our knowledge, is the largest study till date on this matter. We also could investigate a larger number of autoantibodies compared to previous studies. 1 In our study, the size of pericardial effusion was the prime determinant of development of tamponade, yet, in patients with lupus, tamponade can develop in moderate and even small sized effusions (smallest linear echocardiographic dimension associated with development of tamponade in our cohort was 6 mm). Predictors are important especially in these patients with not so large effusion. We demonstrated that presence of concomitant pleuritis and anti-nucleosome antibody positivity are significant predictors. Association of anti-nucleosome antibody with tamponade is a new finding and needs further study. Nucleosome is a primary antigenic target in lupus and multiple studies have demonstrated that anti-nucleosome antibodies correlate with global disease, 13 variably with renal lupus activity, 14 and outperformed anti-dsDNA and complements in a recent analyses. 15 Data from a recent systematic review and meta-analysis concluded that anti-nucleosome antibody has equal specificity but higher sensitivity and prognostic value than anti-dsDNA antibodies in the diagnosis of SLE. 16 Lupus nephritis was a common comorbidity in our cohort and previous association of nephritis with antinucleosome antibody positivity may be a cofounder. However, we could not demonstrate an association of lupus nephritis with presence of tamponade, though the association with antinucleosome antibody with tamponade persisted even in multivariate model. It is, therefore, possible that anti-nucleosome antibodies may be an activity-specific biomarkers. Our study had a few limitations, retrospective design and non-availability of full autoantibody profile in pericardial fluid in all patients.
However, we made a few important observations, such as, importance of concomitant pleuritis and anti-nucleosome antibody positivity in addition to size of pericardial effusion as predictors of tamponade. We also feel that immunosuppression with methylprednisolone and IV cyclophosphamide are essential, especially to reduce risk of reaccumulation and surgery.
Key messages
• Simple predictions can aid clinicians to early suspect lupus patients at risk of cardiac tamponade.
• Pleuritis, anti-nucleosome antibody and size of pericardial effusion predict development of cardiac tamponade in lupus.
• High dose glucocorticoids and cyclophosphamide are effective in managing this condition.
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